Gliclagood M 40 Tablet is a combination oral hypoglycemic agent containing Gliclazide 40 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Gliclazide, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily decreases hepatic glucose production and increases peripheral insulin sensitivity, contributing to better glucose uptake and utilization. The synergistic action of these two agents helps achieve optimal blood glucose regulation in patients inadequately controlled by diet and exercise alone. Gliclagood M 40 is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and physical activity. It is important to monitor blood glucose levels regularly to adjust dosage and minimize the risk of hypoglycemia, particularly due to the sulfonylurea component. Caution is advised in patients with renal or hepatic impairment, cardiovascular disease, or conditions predisposing to lactic acidosis. Contraindications include type 1 diabetes, diabetic ketoacidosis, and hypersensitivity to either component. Adverse effects may include gastrointestinal disturbances, hypoglycemia, and rarely, lactic acidosis. Patients should adhere strictly to prescribed regimens and consult healthcare providers for any unusual symptoms or concerns.